NOUV Stock Overview
A development stage company, engages in the development of nutraceuticals products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Nouveau Life Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0003 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | -50.00% |
| 3 Month Change | -50.00% |
| 1 Year Change | -50.00% |
| 33 Year Change | -88.89% |
| 5 Year Change | -66.67% |
| Change since IPO | -99.97% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| NOUV | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 9,900.0% | 2.6% | 0.5% |
| 1Y | -50.0% | 13.1% | 30.7% |
Return vs Industry: NOUV underperformed the US Pharmaceuticals industry which returned 13.1% over the past year.
Return vs Market: NOUV underperformed the US Market which returned 30.7% over the past year.
Price Volatility
| NOUV volatility | |
|---|---|
| NOUV Average Weekly Movement | 6,653.1% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NOUV's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NOUV's weekly volatility has increased from 3330% to 6653% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Brian Shibley | n/a |
Nouveau Life Pharmaceuticals, Inc., a development stage company, engages in the development of nutraceuticals products. It provides natural alternatives and prescription drugs. The company was formerly known as Hybrid Fuels, Inc. and changed its name to Nouveau Life Pharmaceuticals, Inc. in May 2012.
Nouveau Life Pharmaceuticals, Inc. Fundamentals Summary
| NOUV fundamental statistics | |
|---|---|
| Market cap | US$666.10k |
| Earnings (TTM) | -US$503.31k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs NOUV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOUV income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$503.32k |
| Earnings | -US$503.31k |
Last Reported Earnings
Mar 31, 2008
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did NOUV perform over the long term?
See historical performance and comparison